1171892-40-2

Basic information

• Product Name: 3-ethoxy-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridine
• Synonyms: 3-ethoxy-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridine;5-Ethoxypyridine-3-boronic acid pinacol ester
• CAS NO: 1171892-40-2
• Molecular Formula: C13H20BNO3
• Molecular Weight: 249.1138
• Mol File: 1171892-40-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 360.8±27.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.79±0.10(Predicted)
• CAS DataBase Reference: 3-ethoxy-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ethoxy-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridine(1171892-40-2)
• EPA Substance Registry System: 3-ethoxy-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridine(1171892-40-2)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 1171892-40-2(Hazardous Substances Data)

Usage

Uses

3-Ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is a reagent used for the synthesis of a mesoporous organosilica grafted palladium (II) catalyst.

Upstream product

• 74115-13-2 5-bromopyridine-3-ol 
• 17117-17-8 5-bromo-3-ethoxypyridine 
• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS

The present invention provides compounds of formula (I) that are PDEl enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to the use of 1 H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1 H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1 H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1 H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1 H-imidazo[4,5-c]quinolinone compounds.